Hyamax

Hyamed SA, dedicated to the research, production, and sales of high-end medical aesthetics products such as soft tissue injectable fillers, injectable lipolysis series pharmaceuticals, and medical aesthetic surgical series, has embarked on a new journey of "technology empowering beauty, beauty creating value." On the path of technological exploration, Hyamed advocates sincere cooperation and joint efforts. With its R&D center based in Switzerland, Hyamed continuously enhances the technical capabilities of its Zhuhai production and R&D base. The company maintains deep collaborations with multiple universities including Université Savoie Mont Blanc, the Swiss FE Life Science Foundation, the University of Geneva, Xi’an Jiaotong University, Jinan University, Jilin University, and Zunyi Medical University. It has achieved repeated breakthroughs in the technological development of injectable series products, silicone rubber series products, and PTFE expanded polytetrafluoroethylene series products. Safety and efficacy remain the "brand hallmark" of Hyamed products. The first phase of the Zhuhai R&D base includes a 15 million square-foot, 10,000-class clean production workshop, primarily used for the R&D and production of high-end medical aesthetics products and pharmaceuticals. In 2022, Hyamed will gradually launch high-end medical aesthetic products such as hyaluronic acid injections, exosomes, recombinant humanized collagen, and medical dressings, fully developing a complete range of high-end medical aesthetic products including Class III medical devices, Class II medical devices, and cosmetics to meet the diverse needs of beauty seekers.